openPR Logo
Press release

Investigation announced for Investors who lost money with shares of Entrada Therapeutics, Inc. (NASDAQ: TRDA)

01-18-2024 07:37 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Entrada Therapeutics, Inc. (NASDAQ: TRDA) shares over potential securities laws violations.

An investigation for investors in Entrada Therapeutics, Inc. (NASDAQ: TRDA) shares over potential securities laws violations.

An investigation was announced for investors of Entrada Therapeutics, Inc. (NASDAQ: TRDA) shares over potential securities laws violations by Entrada Therapeutics, Inc.

Investors who purchased shares of Entrada Therapeutics, Inc. (NASDAQ: TRDA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Entrada Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Boston, MA based Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. On December 19, 2022, Entrada Therapeutics, Inc. annoucned that the U.S. Food and Drug Administration ("FDA") placed a clinical hold on the Company's Investigational New Drug Application for ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy. The FDA indicated that they would provide an official Clinical Hold letter to Entrada within 30 days. On this news, Entrada's stock price fell $3.93 per share, or 19.76%, to close at $15.96 per share on December 20, 2022. Then, on November 22, 2023, Entrada announced that after reevaluating additional information on ENTR-601-44, the FDA refused to lift the previously announced clinical hold on its Phase 1 trial.

Shares of Entrada Therapeutics, Inc. (NASDAQ: TRDA) closed on January 17, 2024, at $15.51 per share.

Those who purchased shares of Entrada Therapeutics, Inc. (NASDAQ: TRDA) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors who lost money with shares of Entrada Therapeutics, Inc. (NASDAQ: TRDA) here

News-ID: 3354792 • Views:

More Releases from Shareholders Foundation

ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly NASDAQ: SINA)
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made. If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: FLR) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp. (NYSE: SOC)
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp. Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc. (NASDAQ: LNTH)
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Entrada

AI-Based Medical Transcription Market Hits New High | Major Giants Notable, ZyDo …
HTF MI just released the Global AI-Based Medical Transcription Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach. Major companies profiled in AI-Based Medical Transcription Market are: M*Modal,
Medical Transcription Software Market Is Going to Boom | Big Giants Entrada, Emd …
HTF MI recently introduced Global Medical Transcription Software Market study with 143+ pages in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status (2024-2032). The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence. Some key players from the complete study are Nuance Communications, Acusis, iMedX, ZyDoc, MModal, Voicebrook, Dolbey Systems, ChartNet Technologies, SpeechRite,
Clinical Documentation Software Market Outlook, Growth Rate, Demands, Trend, Siz …
Clinical Documentation Software Market research report contains a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies interspersed with relevant data. Furthermore, the report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. It also examines market performance and
Automatic Speech Recognition (ASR) Software Market to Witness Huge Growth by 202 …
HTF MI released a new market study on Global Automatic Speech Recognition (ASR) Software Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. The research
Global Medical Transcription Software Market Forecast 2018-2025 Acusis, Entrada, …
Global Medical Transcription Software Market 2018 Research Report proffers an acknowledged and extensive analysis of the immediate state of Medical Transcription Software Market 2018. It analyses the important factors of the Medical Transcription Software market based on present industry situations, Medical Transcription Software market demands, business strategies utilized by Medical Transcription Software market players and the future prospects from various angles in detail. Medical Transcription Software Industry analysis is a
Global Speech Recognition Software Market Size, Status and Forecast 2022 - Lyrix …
ResearchMoz added Latest Research Report titled " Global Speech Recognition Software Market Size, Status and Forecast 2022 " to it's Large Report database. This report studies the global Speech Recognition Software market, analyzes and researches the Speech Recognition Software development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Speechlogger Brainasoft Nuance LilySpeech Smart Action Company Lyrix Go Transcribe Protokol NeoSpeech Request for Sample PDF of